LON:SBTX

SkinBioTherapeutics Interim Earnings Results & Report

SkinBioTherapeutics logo
GBX 4 -0.25 (-5.88%)
As of 03:48 AM Eastern

SkinBioTherapeutics reported Interim earnings on June 8, 2026. The company reported EPS of -GBX 0.31, while revenue was £2.17 million.

Earnings Announcement Details

Quarter
Interim
Report Date
Time
Before Market Opens

SkinBioTherapeutics EPS Results

Actual EPS
-GBX 0.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SkinBioTherapeutics Revenue Results

Actual Revenue
£2.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

SkinBioTherapeutics Interim Earnings FAQ

SkinBioTherapeutics (LON:SBTX) reported earnings of -GBX 0.31 per share for Interim. The report was announced on Monday, June 8, 2026.

SkinBioTherapeutics reported revenue of £2.17 million for Interim.

SkinBioTherapeutics Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
SkinBioTherapeutics Stock Price History
See More SkinBioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SkinBioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SkinBioTherapeutics and other key companies, straight to your email.

About SkinBioTherapeutics

SkinBioTherapeutics (LON:SBTX), a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

View SkinBioTherapeutics Profile